Validated frameworks; observed GMR not relevant [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2017-02-22 11:03 (1423 d 14:58 ago) – Posting: # 17096
Views: 10,754

Hi Yura,

» If the ratio of AUC and Cmax T / R beyond 0.95 - 1.05, whether it is a violation of the conditions of the calculation for algorithm of adaptive design? :confused:

Adjusted alphas of the published frameworks are only valid for certain ranges of n1/CV-combinations, fixed GMRs, and target powers assessed (see this presentation, slide 20). F.i. Potvin’s αadj 0.0294 in ‘Method B’ (“Type 1”) is valid for n1 12–60, CV 10–100%, fixed GMR 0.95, and target power 80%. The maximum Type I Error is generally seen at small stage 1 sample sizes and low CVs. Hence, even if the n1 and/or CV were outside the validated range on the upper end (say for ‘Method B’ >60 and/or >100%) you can be pretty sure that the patient’s risk is still controlled. However, in such a case picky assessors might ask for simulations.
I would avoid performing the first stage in 12 subjects. Due to dropouts one may end up outside the validated range. Example for ‘Method B’:

power.2stage(CV=0.2, n1=12, alpha=c(0.0294, 0.0294), theta0=1.25,
             targetpower=0.8, pmethod="shifted", nsims=1e6)$pBE
# [1] 0.046352 #
n1 within validated range: TIE <0.05.
power.2stage(CV=0.2, n1=10, alpha=c(0.0294, 0.0294), theta0=1.25,
             targetpower=0.8, pmethod="shifted", nsims=1e6)$pBE
# [1] 0.048389 #
n1 outside validated range: higher TIE but still <0.05.

The GMR observed in the first stage is not relevant.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,303 posts in 4,441 threads, 1,488 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Saturday 02:01 UTC (Europe/Vienna)

If you can’t solve a problem, then there is an easier problem
you can solve: find it.    George Pólya

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz